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Wehavedevelopedethylenedicysteine-glucosamine(ECG)asanalternativeto 18F-ﬂuoro-2-deoxy-D-glucose(18F-FDG)forcancer
imaging. ECG localizes in the nuclear components of cells via the hexosamine biosynthetic pathway. This study was to evaluate the
feasibilityofimagingmesotheliomawith 99mTc-ECGand 68Ga-ECG.ECGwassynthesizedfromthiazolidine-4-carboxylicacidand
1,3,4,6-tetra-O-acetyl-2-amino-D-glucopyranose,followedbyreductioninsodiumandliquidammoniatoyieldECG(52%).ECG
was chelated with 99mTc/tin (II) and 68Ga/69Ga chloride for in vitro and in vivo studies in mesothelioma. The highest tumor uptake
of 99mTc-ECG is 0.47 at 30min post injection, and declined to 0.08 at 240min post injection. Tumor uptake (%ID/g), tumor/lung,
tumor/blood, and tumor/muscle count density ratios for 99mTc-ECG (30–240min) were 0.47 ±0.06 to 0.08 ±0.01; 0.71 ±0.07 to
0.85 ± 0.04; 0.47 ± 0.03 to 0.51 ± 0.01, and 3.49 ± 0.24 to 5.06 ± 0.25; for 68Ga-ECG (15–60min) were 0.70 ± 0.06 to 0.92 ± 0.08;
0.64 ± 0.05 to 1.15 ± 0.08; 0.42 ± 0.03 to 0.67 ± 0.07, and 3.84 ± 0.52 to 7.00 ± 1.42; for 18F-FDG (30–180min) were 1.86 ± 0.22
to 1.38 ± 0.35; 3.18 ± 0.44 to 2.92 ± 0.34, 4.19 ± 0.44 to 19.41 ± 2.05 and 5.75 ± 2.55 to 3.33 ± 0.65, respectively. Tumor could
be clearly visualized with 99mTc-ECG and 68Ga-ECG in mesothelioma-bearing rats. 99mTc-ECG and 68Ga-ECG showed increased
uptake in mesothelioma, suggesting they may be useful in diagnosing mesothelioma and also monitoring therapeutic response.
1.Introduction
Drug discovery is accelerating due to mapping of molecular
targets and the rapid synthesis of high-throughput in vitro
testing of compounds in their early stage of the drug de-
velopment process. The development of radiolabeled bio-
chemical compounds, understanding molecular pathways
and imaging devices to detect the radioactivity by external
imaging, has expanded the use of nuclear molecular imaging
studies in drug development. Nuclear molecular imaging
provides vascular angiogenesis, cellular translational, and
transcriptional information. The important applications in
molecular imaging in oncology are at the characterization
of tumors (degree of malignancy), optimal dosing deter-
mination,diﬀerentiation(i.e.,inﬂammation/infectionversus
recurrence, sensitive versus resistant, low versus high grade),
and prediction of treatment response (i.e., select patient
who may respond to therapy). Thus, molecular imaging
helps to control and monitor dosage for increased safety and
eﬀectiveness. The focus of molecular imaging in oncology is
to identify tumor-speciﬁc markers and apply these markers
for evaluation of patient response to treatment. Nuclear
molecular imaging could noninvasively assess diseases treat-
ment endpoints which used to rely almost exclusively on
biopsies and histopathological assays. 18F-Fluoro-deoxy-
glucose (18F-FDG), a gold standard for molecular imaging,
utilizes glucose transporters and hexokinase phosphorylated
processes for tumor imaging [1]. However, 18F-FDG has sev-
eral limitations that give rise to false positive/negative results
[2]. 18F-FDG has poor diﬀerentiation between tumor and
inﬂammation/infection due to its high uptake in granulo-
cytes and macrophages. Therefore, it is amenable to develop
a radiotracer as an alternative for better diﬀerentiation in
tumor imaging.2 Journal of Biomedicine and Biotechnology
Glucosamine enters into cells via hexosamine biosyn-
thetic pathway and its regulatory products of glucosamine-
6-phosphate mediate insulin activation, downstream signal-
ing, glycosylation, and tumor growth. In the hexosamine
pathway, upregulated glucose transporters induce overex-
pression of glutamine: fructose-6-phosphate amidotrans-
ferase (GFAT). GFAT uses the amide group of glutamine to
convert fructose 6-phosphate to glucosamine 6-phosphate
and forms hexosamine products [3]. Phosphorylated glu-
cosamine interacts with uridine diphosphate (UDP) to form
UDPN-acetylglucosamine (UDP-GlcNAc). The dynamic
glycosylation of serine or threonine residues on nuclear and
cytosolic proteins by O-linked protein N-acetylglucosamine
(O-GlcNAc) transferase is abundant in all multicellular
eukaryotes. Glycosylation is a part of posttranslational mod-
iﬁcation and appears to modify a large number of nucleocy-
toplasmic proteins. O-GlcNAc transferase (OGT) activity is
exquisitelyresponsivetointracellularUDP-GlcNAcandUDP
concentrations, which are in turn highly sensitive to glucose
concentrations and other stimuli [4]. In cell nucleus, the
ubiquitous transcription factor Sp1 is extensively modiﬁed
by O-GlcNAc. Sp1 becomes hyperglycosylated in response to
hyperglycemia or elevated glucosamine [4]. Because O-
GlcNAc is involved in hexosamine pathway and nucleus
activity, it becomes an attractive imaging agent for diﬀeren-
tial diagnosis in cancers.
68Ga (89% positron, 68min half-life) and 99mTc
(140keV, 6hrs half-life) are obtained from generators on-
site and have signiﬁcant commercial interest. 68Ga and 99mTc
could provide serial images which are pivotal to clinical
applications by positron emission tomography (PET) and
single photon emission-computed tomography (SPECT).
PET/SPECT/CTisbetterthanPETandSPECTalonebecause
multiple slices by CT and serial images by PET and SPECT
provide a better delineation in tumor volumes. L,L-ethylene-
dicysteine(EC),afamilyofbisaminoethanethiol,isknownto
form stable metal complexes [5, 6]. The strong metal com-
plexing property of such EC systems is also applied for
labeling of small molecules, proteins, and peptides after con-
jugation to EC derivatives. EC-technology platform has
shown to coordinate radiometals and metals for image-guid-
ed target assessment, theranostic applications, and the selec-
tion of patient for treatment [7–19].
Mesothelioma is a cancer caused by exposure to asbestos.
Asbestos ﬁbers have been shown to alter the function and
secretory properties of macrophages, ultimately creating
conditions which favor the development of mesothelioma.
Following asbestos phagocytosis, macrophages generate in-
creased amounts of hydroxyl radicals which are thought to
promote asbestos carcinogenicity. Furthermore, genetic al-
terationsinasbestos-activatedmacrophagesmayresultinthe
release of potent mesothelial cell mitogens such as platelet-
derived growth factor and transforming growth factor-β
which, in turn, may induce the chronic stimulation and
proliferation of mesothelial cells after injury by asbestos
ﬁbers.Althoughtherehavebeensomemodestimprovements
in prognosis from newer chemotherapies and multimodal-
ity treatments, the prognosis for malignant mesothelioma
remains poor. The standard approaches such as radiation,
chemotherapy, and surgery have been investigated to treat
patients with malignant pleural mesothelioma. Treatment
of malignant mesothelioma at earlier stages has a better
prognosis, but cures are exceedingly rare. Immunohisto-
chemical analysis has shown that GlcNAc-speciﬁc binding
sites are useful for distinguishing metastatic carcinoma
from mesothelioma in human [20]. Subsequently, EC-glu-
cosamine (ECG), a glucose analogue, is developed to trace
the glucose transport system and glucosamine binding sites
in mesothelioma. 99mTc-ECG and 68Ga-ECG may assess the
staging,restaging,andresponsemonitoringinmesothelioma
for early and right medication of this disease.
2.MaterialsandMethods
2.1. General. All chemicals and solvents were obtained from
Sigma-Aldrich (St. Louis, MO). Nuclear magnetic resonance
(NMR) was performed on Bruker 300MHz Spectrometer,
and mass spectra were performed on Waters Q-TOF Ultima
Mass Spectrometer (Milford, MA) at the core facility at the
University of Texas MD Anderson Cancer Center (UTM-
DACC, Houston, TX). Chemical shifts were reported in
δ (ppm) and J values in Hertz. FDG was obtained from
Department of Nuclear Medicine at UTMDACC.
2.2. Synthesis of ECG
2.2.1. Step 1: Synthesis of T-G-(Ac)4. To a solution of thia-
zolidine-4-carboxylic acid (T) (2.6g, 0.02mol) in DMF
(20mL)and5.0mLtrimethylamine,1-hydroxybenzotriazole
hydrate 2.7g (0.02mol) was added. After 30min, 1,3,4,6-
tetra-O-acetyl-2-amino-α-D-glucopyranose hydrochloride
(G-(Ac)4)(7.7g,0.02mol),N,N -di-cyclohexylcarbodiimide
(DCC; 4.2g, 0.02mol), and 4-dimethylaminopyridine
(DMAP; 1.2g, 0.01mol) were added to the mixture and
stirred for overnight at room temperature. The solution was
evaporated to dryness at high vacuum. Dichloromethane
(CH2Cl2) (50mL) was added to the residual and kept at
4◦C for overnight, then ﬁltered. The product was puriﬁed
with silica gel by eluting with CH2Cl2/MeOH (95/5, V/V)
to yield white product T-G-(Ac)4 4.08g (44.2%). NMR and
mass spectrometry were used to conﬁrm the structure of
T-G-(Ac)4.
2.2.2. Step 2: Reduction Reaction. Sodium was added piece
by piece to a solution of T-G-(Ac)4 (4.08g, 8.8mmol) in
liquid ammonia (170g). The color of the solution was slowly
changedtodarkblue.After30minutes,alittleofammonium
chloride was added. The liquid ammonia was removed by
reduced pressure. The residual solid was triturated with
methanol (100mL). The solid was then ﬁltered and washed
with additional methanol (50mL) to yield crude product
4.16g. To obtain analytical pure ECG, the crude product
(0.1g) was dissolved in 1.0mL of HCl (0.1N) and puriﬁed
with sephadex column by eluting with H2O. The aqueous
fractions were combined and lyophilized to yield EC-G
0.029g (46.7%). NMR, mass spectrometry, and HPLC were
used to conﬁrm the structure of ECG.Journal of Biomedicine and Biotechnology 3
2.3. Synthesis of Cold Ga-ECG. 69GaCl3 (20mg, 0.11mmol)
in 0.2mL H2O was added to a solution of ECG (60mg,
0.1mmol) in 0.5mL H2O. The pH value was adjusted to
4-5 with 0.1N NaOH (50μL). The solution was heated for
30min at 60◦C. The product was puriﬁed by a sephadex
column eluting with H2O to yield Ga-ECG. After lyophiliza-
tion, Ga-ECG was obtained as white solid (52mg, 78.1%).
NMR, mass spectrometry, and HPLC were used to conﬁrm
the structure of 69Ga-ECG.
2.4. Radiosynthesis of 68Ga-ECG and 99mTc-ECG. 68GaCl3
was obtained from a 68Ge/68Ga generator (Eckert Ziegler,
Valencia, CA) eluted with 0.1N HCl. 68GaCl3 (120μL,
300μCi)wasaddedtothesolutionofECG(1.2mg)in0.1mL
H2O,andpHvaluewasadjustedto4-5withNaHCO3 (40μL,
0.1N). The solution was heated at 60◦C for 15min. Sodium
pertechnetate (Na99mTcO4) was obtained from 99Mo/99mTc
generator by Covidien (Houston, TX). Radiosynthesis of
99mTc-ECG was achieved by adding 99mTc-pertechnetate
(40–50mCi) into the lyophilized residue of ECG (5mg) and
tin (II) chloride (SnCl2, 100μg). The complexation of ECG
with 99mTc was carried out at pH 6.5. Radiochemical purity
was determined by TLC (Waterman No. 1, Aldrich-Sigma,
St. Louis, MO) eluted with saline. High-performance liquid
chromatography (HPLC), equipped with a NaI detector
a n dU Vd e t e c t o r( 2 1 0 n m ) ,w a sp e r f o r m e do naC - 1 8
reversephasecolumn(C18-extend,Agilent,SantaClara,CA)
eluted with acetonitrile/water (1:9, V/V) at a ﬂow rate of
0.5mL/min. HPLC of cold 69Ga-ECG was used to conﬁrm
the structure of 68Ga-ECG.
2.5. Biodistribution of Radiotracers in Mesothelioma-Bearing
Rats. Female Fischer 344 rats (150 ± 25g) (Harlan Sprague-
Dawley, Indianapolis, IN) (n = 3 rats/time point) were inoc-
ulated with malignant pleural mesothelioma cells derived
from the IL-45 cell line. Tumor cells (106 cells/rat) were
injected (i.m.) into the hind legs. Studies were performed 14
to17daysafterinoculationwhentumorswereapproximately
1cm in diameter. In tissue distribution studies, each animal
was injected (iv, 10μCi/rat, 10μg/rat) with 99mTc-ECG,
68Ga-ECG, and 18F-FDG. Rats were sacriﬁced at 0.5–4hrs.
The selected tissues were excised, weighed, and counted for
radioactivity by using a gamma counter (Packard Instru-
ments, Downers Grove, IL). The biodistribution of tracer in
each sample was calculated as percentage of the injected dose
per gram of tissue wet weight (%ID/g).
2.6. Scintigraphic Imaging Studies. Female Fischer 344 rats
(150 ± 25g) bearing malignant pleural mesothelioma (at
hind legs) derived from the IL-45 cell line were used for
imaging studies. Studies were performed 14 to 17 days
after inoculation when tumors were approximately 1cm in
diameter. Scintigraphic images were obtained either from a
micro-PET (Inveon) embedded in the gantries coordinate
PET/CT data acquisition or from an M-gamma cam-
era (Siemens Medical Systems, Inc., Hoﬀman Estates, IL)
equipped with low-energy parallel-hole collimator. Each
animal was administered with 99mTc-ECG (300μCi/rat,
iv), 68Ga-ECG, and 18F-FDG (400μCi/rat, iv), and the
images were obtained at 0.5–4hrs. To demonstrate 68Ga-
ECG could be used for image-guided therapy, the same
mesothelioma-bearing rats (n = 3) at tumor volume 1.5cm
were treated with paclitaxel (20mg/kg, iv, single injection).
Prior to treatment and postpaclitaxel treatment on day 7,
the tumor-bearing rats were imaged with 68Ga-ECG. Com-
puter-outlined regions of interest (ROI) (counts per pixel)
were used to determine tumor-to-background count density
ratios for 99mTc-ECG. Computer outlined regions of interest
(ROI) (counts per pixel) for tumor and muscle at the
corresponding time interval were used to generate a dynamic
plot for 68Ga-ECG and 18F-FDG. Dynamic plot was from 0
to 45 minutes. Paclitaxel was selected because it produced
antiproliferative eﬀects by inhibition of glucose transporters
(Glut-1) in cell line studies [21]. Also, it has been reported
that mesothelioma responds to paclitaxel treatment in the
animal model [22].
3. Result
3.1. Chemistry. The synthetic scheme is shown in Figure 1.
ECG was synthesized by two-step reactions. In the ﬁrst step,
thiazolidine-4-carboxylic acid (T) was reacted with 1,3,4,6-
tetra-O-acetyl-2-amino-α-D-glucopyranose hydrochloride
(G-(Ac)4)inthepresenceof1-hydroxybenzotriazolehydrate,
DCC, and DMAP. After puriﬁcation, the yield of product
T-G-(Ac)4 was 44.2%. 1H NMR (D2O, δ): 1.97–2.14 (m,
12H), 3.88 (t, 1H), 3.93 (s, 2H), 4.05–4.10 (m, 6H) 4.22–4.30
(m,2H),5.09(t,1H),5.34(t,1H),5.80(d,1H),6.93(d,1H).
13C NMR (D2O, δ): 171.19, 171.00, 170.65, 169.35, 166.35,
141.76, 92.05, 82.45, 72.79, 72.02, 68.02, 61.73, 60.39, 53.21,
42.32, 20.84, 20.68, 20.58, 20.55. FAB MS m/z: 462.5.
In the second step, T-G-(Ac)4 was reduced by sodium
in liquid ammonia (Birch reduction). The crude product
was puriﬁed with a sephadex column to yield ECG (46.7%).
HPLC shows that purity is over 82%. 1HN M R( D 2 O ,δ):
3.15–3.20 (m, 4H), 3.78–4.05 (m, 6H), 4.08–4.15 (m, 8H),
4.2-4.3 (d, 2H), 4.68–4.73 (d, 2H), 5.19–5.21 (d, 2H). 13C
NMR (D2O, δ): 174.81, 174.56, 94.95, 90.87, 90.84, 75.96,
73.91, 73.85, 71.59, 70.71, 70.66, 70.10, 69.88, 60.72, 60.62,
56.72, 54.11, 23.33, 22.23, 21.96. FAB MS m/z: 591.
N M Ro fc o l d69Ga-ECG was 1H NMR (D2O, δ): 2.94–
3.38 (m, 8H), 3.43–3.65 (m, 4H), 3.50–3.80 (m, 10H), 3.92–
4.02 (t, 2H), 4.23–4.34 (d, 2H), 5.15–5.34 (d, 2H), 13CN M R
(D2O, δ): 175.51, 175.16, 95.55, 90.85, 90.67, 75.76, 74.90,
73.55, 71.59, 70.71, 70.66, 70.10, 69.88, 60.72, 60.62, 56.72,
54.11, 23.53, 22.83, 22.16. Radio-TLC and HPLC analyses
of the purity of 68Ga-ECG and 99mTc-ECG were > 96%
(Figures 2–4). HPLC of cold 69Ga-ECG was used to conﬁrm
the structure of 68Ga-ECG (Figure 3).
3.2. In Vivo Biodistribution Studies. Tumor and tissue uptake
(%ID/g) of 68Ga-ECG, 99mTc-ECG and 18F-FDG are shown
in Tables 1, 2,a n d3. The highest tumor uptake of 99mTc-
ECG is 0.47 at 30min after injection, and declined to 0.08 at
240min after injection. Tumor uptake (%ID/g), tumor/lung,
tumor/blood, and tumor/muscle count density ratios for4 Journal of Biomedicine and Biotechnology
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Figure 1: Eﬃcient synthesis of ECG.
Table 1: Biodistribution of 68Ga-ECG in mesothelioma-bearing rats.
Percentage of injected dose per gram of tissue weight (n = 3/time, interval, iv)1
15min 30min 60min
Blood 1.66 ±0.06 1.54 ±0.02 1.38 ± 0.03
Heart 0.51 ±0.04 0.39 ±0.04 0.40 ± 0.03
Lung 1.07 ±0.02 0.94 ±0.04 0.80 ± 0.04
Thyroid 0.88 ±0.07 0.96 ±0.11 0.83 ± 0.05
Pancreas 0.29 ±0.02 0.28 ±0.03 0.29 ± 0.03
Liver 0.77 ±0.05 0.71 ±0.07 0.78 ± 0.04
Spleen 0.41 ±0.03 0.44 ±0.07 0.49 ± 0.01
Kidney 1.53 ±0.06 0.75 ±0.04 0.70 ± 0.02
Stomach 0.29 ±0.07 0.37 ±0.02 0.40 ± 0.04
Intestine 0.31 ±0.04 0.35 ±0.05 0.53 ± 0.01
Uterus 0.87 ±0.19 0.81 ±0.04 0.77 ± 0.10
Tumor 0.70 ±0.06 0.72 ±0.06 0.92 ± 0.08
Muscle 0.18 ±0.01 0.14 ±0.01 0.14 ± 0.02
Bone 0.27 ±0.02 0.51 ±0.09 0.46 ± 0.02
Brain 0.05 ±0.01 0.07 ±0.01 0.08 ± 0.01
Tumor/blood 0.42 ±0.03 0.47 ±0.04 0.67 ± 0.07
Tumor/muscle 3.84 ±0.52 5.63 ±1.03 7.00 ± 1.42
Tumor/brain 11.68 ±1.87 8.81 ±1.54 13.20 ±2.78
Tumor/lung 0.64 ±0.05 0.78 ±0.10 1.15 ± 0.08
1Values represent the mean ± standard deviation of data from 3 animals.Journal of Biomedicine and Biotechnology 5
Table 2: Biodistribution of 99mTc-ECG in mesothelioma-bearing rats.
Percentage of injected dose per gram of tissue weight (n = 3/time, interval, iv)1
30min 2h 4h
Blood 0.98 ±0.06 0.23 ±0.03 0.16 ±0.01
Heart 0.28 ±0.02 0.06 ±0.01 0.04 ±0.00
Lung 0.65 ±0.03 0.16 ±0.03 0.10 ±0.00
Thyroid 0.55 ±0.04 0.12 ±0.02 0.08 ±0.00
Pancreas 0.21 ±0.02 0.05 ±0.01 0.04 ±0.01
Liver 1.05 ±0.02 0.86 ±0.07 0.51 ±0.02
Spleen 0.59 ±0.05 0.61 ±0.07 0.70 ±0.02
Kidney 3.79 ±0.57 2.02 ±0.49 1.33 ±0.10
Stomach 0.35 ±0.03 0.07 ±0.01 0.03 ±0.00
Intestine 0.28 ±0.02 0.11 ±0.04 0.04 ±0.01
Uterus 0.55 ±0.04 0.15 ±0.06 0.08 ±0.01
Tumor 0.47 ±0.06 0.12 ±0.01 0.08 ±0.00
Muscle 0.13 ±0.01 0.03 ±0.01 0.02 ±0.00
Bone 0.16 ±0.06 0.05 ±0.01 0.03 ±0.00
Brain 0.04 ±0.00 0.01 ±0.00 0.01 ±0.00
Tumor/blood 0.47 ±0.03 0.50 ±0.03 0.51 ±0.00
Tumor/muscle 3.49 ±0.24 3.75 ±0.44 5.06 ±0.25
Tumor/brain 10.79 ±0.50 10.22 ±1.37 15.52 ±0.89
Uterus/muscle 4.18 ±0.23 4.49 ±0.96 4.74 ±0.16
Tumor/lung 0.71 ±0.07 0.75 ±0.10 0.85 ±0.04
1Values represent the mean ± standard deviation of data from 3 animals.
Table 3: Biodistribution of 18F-FDG in mesothelioma-bearing rats.
Percentage of injected dose per gram of tissue weight (n = 3/time, interval, iv)1
30min 90min 180min
Blood 0.45 ±0.07 0.15 ±0.01 0.07 ±0.01
Heart 3.42 ±1.14 1.95 ±0.40 1.94 ±0.45
Lung 0.60 ±0.07 0.53 ±0.03 0.46 ±0.06
Thyroid 0.65 ±0.04 0.47 ±0.05 0.54 ±0.04
Pancreas 0.22 ±0.02 0.21 ±0.02 0.21 ±0.03
Liver 0.51 ±0.08 0.33 ±0.03 0.23 ±0.03
Spleen 0.88 ±0.08 0.87 ±0.06 0.98 ±0.10
Kidney 0.85 ±0.13 0.43 ±0.04 0.23 ±0.01
Stomach 0.55 ±0.03 0.40 ±0.03 0.38 ±0.02
Intestine 0.94 ±0.16 1.00 ±0.22 0.62 ±0.07
Uterus 0.52 ±0.06 0.57 ±0.08 0.39 ±0.09
Tumor 1.86 ±0.22 1.63 ±0.19 1.38 ±0.35
Muscle 0.45 ±0.14 0.23 ±0.03 0.42 ±0.06
Bone 0.21 ±0.09 0.14 ±0.07 0.24 ±0.06
Brain 2.36 ±0.10 2.24 ±0.20 1.89 ±0.35
Tumor/blood 4.19 ±0.44 11.01 ±1.60 19.41 ±2.05
Tumor/muscle 5.75 ±2.55 7.40 ±1.67 3.33 ±0.65
Tumor/brain 0.77 ±0.09 0.72 ±0.02 0.71 ±0.05
Uterus/muscle 1.58 ±0.69 2.50 ±0.37 0.94 ±0.16
Tumor/lung 3.18 ±0.44 3.41 ±0.43 2.92 ±0.34
1Values shown represent the mean ± standard deviation of data from 3 animals.6 Journal of Biomedicine and Biotechnology
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Figure 2: TLC analysis of 68Ga-ECG using saline as an eluant. Radio-TLC analysis of the purity of 68Ga-ECG was >96%.
99mTc-ECG (30–240min) were 0.47 ± 0.06 to 0.08 ± 0.01,
0.71 ± 0.07 to 0.85 ± 0.04, 0.47 ± 0.03 to 0.51 ± 0.01, and
3.49 ± 0.24 to 5.06 ± 0.25; for 68Ga-ECG (15–60min) were
0.70 ± 0.06 to 0.92 ± 0.08, 0.64 ± 0.05 to 1.15 ± 0.08, 0.42 ±
0.03 to 0.67 ± 0.07, and 3.84 ± 0.52 to 7.00 ± 1.42; and for
FDG (30–180min) were 1.86 ± 0.22 to 1.38 ± 0.35, 3.18 ±
0.44 to 2.92 ± 0.34, 4.19 ± 0.44 to 19.41 ± 2.05, and 5.75 ±
2.55 to 3.33 ± 0.65, respectively. Higher kidney uptake
was observed for both 68Ga-ECG and 99mTc-ECG groups,
presumablebecauseECandEC-conjugatesmayinteractwith
renal tubules in the kidney [11].
3.3. Scintigraphic Imaging Studies. Scintigraphic images of
rats administered 68Ga-ECG, 99mTc-ECG, and 18F-FDG
showed that tumors could be clearly visualized at 0.5–4hrs
(Figures5–7).Dynamicplotoftumoruptakewith 68Ga-ECG
and 18F-FDG showed similar transporter pattern (Figure 5).
68Ga-ECG was able to monitor paclitaxel treatment response
in the same mesothelioma-bearing rats (Figure 6). Two rats
receiving 99mTc-ECG (middle and right) were randomly
selected to compare to that of the rat receiving 99mTc-EC
(left) under the same imaging panel. Tumor in99mTc-ECG
group showed much higher uptake than 99mTc-EC (control)
g r o u pa t1a n d2h r s( Figure 7).
4. Discussion
Previous studies have shown that 99mTc-ECG exhibits char-
acteristics similar to 18F-FDG in terms of the glucose mem-
brane transport process and tumor uptake [11]. These glu-
cose membrane transporters are involved in both the gly-
colytic pathway and the hexosamine biosynthetic pathway.
Cell cycle analysis revealed that 99mTc-ECG was able to
transport across the nucleus membrane and involved in
proliferation activity in all phases cell cycles [14]. Moreover,
the thymidine incorporation assay studies showed similar
uptake patterns for both unlabeled ECG and glucose,
suggesting that both ECG and glucose were involved in the
proliferation/growthactivityofcells,whereasunlabeledFDG
was not [14].Journal of Biomedicine and Biotechnology 7
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Figure 3: HPLC analysis of 68/69Ga-ECG and ECG (mobile phase: H2O/acetonitrile, 9:1 V/V, ﬂow rate: 0.5mL/min, column: C18-extend
(Agilent), UV ABS 210nm). HPLC analysis of the purity of 68Ga-ECG was >96%.
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Figure 4: ITLC (a, in saline) and HPLC (b, NaI detector) analysis of 99mTc-ECG (mobile phase: H2O/acetonitrile, 9:1 V/V, ﬂow rate:
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The lack of 18F-FDG involvement in DNA proliferation
is attributable to the presence of the ﬂuorine atom at
position 2 of the molecule, which prevents its metabolism
and consequently its utilization in cell proliferation and
growth [23]. As both molecules enter a cell and become
phosphorylated by hexokinase, it can be diverted from the
main glycolytic/glycogen pathways into accessory pathways.
For example, under normal conditions, cells utilize 95%
glucose which is transported via transporters 1 and 3
through the glycolytic pathway. 18F-FDG uses transporters
1a n d3 .99mTc-ECG uses transporters 2 and 4 which are
the transporters for glucosamine and transport glucose by
the hexosamine pathway under normal conditions [24].
In addition, under abnormal conditions, only 3 to 5% of
glucose is being utilized by the glycolytic pathway. However,
in the case where an abnormal condition exists, there is a
dramatic shift from 95% and above [25]. It should be noted
that when the cell senses stress or a disease state occurs,
the cells become hyper and glucose deﬁcient/depleted, which
in turn deactivates the glycolytic pathway. The hexosamine
biosynthesis pathway then becomes active and takes over.
The proliferation rates for tumors are with 100–1000x more8 Journal of Biomedicine and Biotechnology
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Figure 5: 18F-FDG and68Ga-ECG PET imaging in mesothelioma-
bearing rats (400μCi/rat, iv, acquired 45 minutes). Computer-
outlined regions of interest (ROI) (counts per pixel) for tumor and
muscle at the corresponding time interval were used to generate a
dynamic plot. Dynamic plot was from 0 to 45 minutes.
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Image-guided therapy with 68Ga-ECG in the Mesothelioma-bearing rat
Figure 6: 68Ga-ECG PET images in rat bearing mesothelioma
(400μCi/rat, iv, lower body) before and after treatment at 45
minutes. Top: baseline at tumor size 1.5cm; bottom: treated with
paclitaxel (20mg/kg, iv, single dose on day 7). T: tumor.
than normal cells and thus a relatively greater concentration
of 99mTc-ECG than normal cells. 99mTc-ECG can be utilized
by cancer cells; thus the imaging studies are successful.
Clinical phase 1 and 2 trials revealed that 99mTc-ECG was
safe and had favorable radiation dosimetry. 99mTc-ECG was
able to diﬀerentiate tumor and inﬂammation in lung cancer
patients [26].
In the present study, we are able to place diﬀerent
radiometals in ECG. Both 99mTc-ECG and 68Ga-ECG were
able to image mesothelioma in the animal model. 68Ga-ECG
was able to provide image-guided therapy assessment. From
biodistribution (Tables 1–3), tumor/brain count density
ratios of 99mTc-ECG and 68Ga-ECG were better than those
of FDG. It may have advantage in brain tumor imaging than
FDG. However, tumor/blood count density ratios of 99mTc-
ECG and 68Ga-ECG were less than that of FDG. Additional
experiments such as mechanistic studies and diﬀerential
diagnosis would warrant their applications in oncology.
T/M = 2.86 T/M = 3.7 T/M = 4.1
T/M = 2.8 T/M = 3.47 T/M = 3.91
99mTC-EC 99mTC-ECG 99mTC-ECG
Planar images of mesothelioma-bearing rats with
99mTC-EC and 99mTC-ECG
T
Figure 7: Planar scintigraphy of 99mTc-EC (left) and 99mTc-ECG
(300μCi/rat, iv, acquired 500,000 count) (middle and right) in
mesothelioma-bearing rats. The numbers are tumor-to-muscle
count density ratios at 1hr (upper panel) and 2hrs (lower panel).
T: tumor.
In summary, eﬃcient synthesis of ECG was achieved
with high yield. 68Ga-ECG and 99mTc-ECG were prepared
with high radiochemical purities. Biodistribution and planar
imaging studies demonstrated the pharmacokinetic distri-
bution and feasibility of using 68Ga-ECG and 99mTc-ECG
to image mesothelioma. 68Ga-ECG and 99mTc-ECG showed
an increased uptake in mesothelioma in the model tested,
indicating that they are feasible to assess tumor volume.
68Ga-ECG and 99mTc-ECG may be useful for screening,
diagnosing, staging, and assessing the eﬃcacy of treatment
in respect to all cancer types.
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